Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million
PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration
Nicholas Leupin M.D., Ph.D. appointed as Novocure Chief Medical Officer, effective January 1, 2024
Novocure to present at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PST on Wednesday, January 10, 2024
https://www.businesswire.com/news/home/20240108937202/en/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.